CTCELLS
Latest round
- Series A
Last raised
- Apr 2021
Total raised
- $4.5M
Investors
- 7
About CTCELLS
Founded in 2018 and based in Daegu, South Korea, CTCELLS, Inc. operates as a cancer diagnosis and drug development company. The CEO of the company is Kim Min-Seok. In March 2022, CTCELLS, Inc. CTCELLS, Inc. researches circulating tumor cell or CTC-based cancer diagnosis in the blood which is essential to the development of cell therapy based on MBP technology that attaches protein to the NK cell membrane to increase efficacy, and RACE, a dual antibody technology that activates immune cells (Receptor antibody conjugated engager). The company plans to use the funds for facility investment and recruitment of new personnel. The company also plans to obtain preclinical results for cell therapy and protein therapy programs by the first half of 2023.
Who invested in CTCELLS
7 investors across 2 rounds
See all investors in CTCELLS
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CTCELLS
Who invested in CTCELLS?
CTCELLS has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CTCELLS raised?
CTCELLS has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did CTCELLS last raise money?
CTCELLS's most recent round on record is a Series A, in Apr 2021.
What does CTCELLS do?
Founded in 2018 and based in Daegu, South Korea, CTCELLS, Inc.
Where is CTCELLS headquartered?
CTCELLS is headquartered in Daegu, South Korea.
Which VCs invest in companies like CTCELLS?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at CTCELLS's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like CTCELLS? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.